StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Clarus 1 billion dollar valuation?

<< Previous

Bullboard Posts

Next >>

Comment by kodiakupon Jan 18, 2021 6:39pm

431 Views

Post# 32322945

RE:Clarus 1 billion dollar valuation?

- Several give as an estimate ($ 4) If they deploy aristotle .. nothing less than (16 $) or even more can be . and that is only my opignon....

Stock Forecast & Price Targets

Showing:

All Analyst Consensus & Price Target

Best Performing Analyst Consensus & Price TargetPremium

Analyst Rating Consensus

Moderate Buy

Based on 1 Analyst Ratings

1 Buy
0 Hold
0 Sell

Based on 1 analysts offering stock ratings for StageZero Life Sciences Ltd in the last 3 months (by analysts ranked 0 to 5 stars).

Analyst Price Target on TSE:SZLS

C$5.11

(467.78% Upside)

Based on 1 analyst offering 12 month price targets for StageZero Life Sciences Ltd in the last 3 months. The average price target is C$5.11 with a high forecast of C$5.11 and a low forecast of C$5.11. The average price target represents a 467.78% increase from the last price of C$0.9.